Skip to main content

Table 1 Monoclonal antibodies under clinical trials for the treatment of colorectal cancer

From: Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer

mAb Target Phase Coadministration NCT number
Bevacizumab VEGF-A I/II FOLFIRINOX3 NCT03795311
Bevacizumab VEGF-A II Xelox/Xeliri NCT01531595
Ramucirumab VEGFR2 II TAS 102 NCT03520946
Aflibercept VEGF-A,-B, PlGF II LV5FU2 NCT02384759
Aflibercept VEGF-A,-B, PlGF II mLV5FU2/ mFOLFOX7 NCT03530267
VGX-100 VEGF-C I Bevacizumab NCT01514123
Gevokizumab IL-1β I Standard therapies NCT03798626
Cetuximab EGFR I/II MEN1611 NCT04495621
Cetuximab EGFR III FOLFIRI NCT03391934
Trastuzumab HER2 II Tucatinib NCT03043313
Panitumumab EGFR II FOLFOX,FOLFIRI or irinotecan NCT03311750
Panitumumab EGFR II Niraparib NCT03983993
Nivolumab PD-1 II FOLFOXIRI/Bevacizumab NCT04072198
Nivolumab PD-1 I/II Guadecitabine NCT03576963
Pembrolizumab PD-1 I/II Regorafenib NCT03657641
Pembrolizumab PD-1 I Grapiprant NCT03658772
Atezolizumab PD-L1 II Bevacizumab NCT02982694
Durvalumab PD-L1 II Trametinib NCT03428126
Ipilimumab CTLA-4 II FOLFOX/ Nivolumab NCT04430985
Tremelimumab CTLA-4 I Durvalumab NCT02754856
Genolimzumab PD-1 I Fruquintinib NCT03977090